Status:
COMPLETED
A Study of LY3857210 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy partici...
Eligibility Criteria
Inclusion
- Overtly healthy male or female participants as determined by medical evaluation
- Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive)
- Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential
Exclusion
- Have contraindications to undergoing magnetic resonance imaging (MRI) examination including but not limited to implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, and other medical implants that have not been certified for head MRI
- Have clinically significant findings on the screening MRI scan, as judged by the investigator
- Suffer from claustrophobia and would be unable to tolerate the confined spaces of MRI or PET camera
Key Trial Info
Start Date :
March 17 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05292040
Start Date
March 17 2022
End Date
December 14 2022
Last Update
March 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Invicro, Institute for Neurodegenerative Disorders
New Haven, Connecticut, United States, 06510